Form 8-K

8-K — Liquidia Corp

Accession: 0001104659-26-104929

Filed: 2026-09-03

Period: 2026-09-03

CIK: 0001819576

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2624724d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2624724d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2624724d1_8k.htm · Sequence: 1

false

0001819576

2026-09-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 3, 2026

LIQUIDIA

CORPORATION

(Exact name

of registrant as specified in its charter)

Delaware

001-39724

85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

419

Davis Drive, Suite

100, Morrisville,

North Carolina

27560

(Address of principal executive

offices)

(Zip Code)

Registrant’s telephone number, including

area code: (919) 328-4400

(Former

name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock

LQDA

The

Nasdaq

Stock Market LLC

Indicate by check mark whether the registrant is

an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events.

On September 3, 2026, Liquidia Corporation, a

Delaware corporation (the “Company”), issued a press release announcing that the U.S. Food and Drug Administration has granted

Fast Track Designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud’s phenomenon

associated with systemic sclerosis. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference into

this Item 8.01.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibit

No.

Exhibit

99.1

Press Release of Liquidia Corporation, dated September 3, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

September 3, 2026

Liquidia Corporation

By:

/s/ Michael Kaseta

Name: Michael Kaseta

Title: Chief Financial Officer and Chief Operating Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2624724d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment

of Raynaud's Phenomenon Associated with Systemic Sclerosis

· Fast Track designation underscores the significant unmet need for patients

with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients

· No therapy is currently approved in the U.S. to treat SSc-RP and management

options are limited and often inadequate for patients with more severe disease

· Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA

in SSc-RP, in the fourth quarter of 2026

MORRISVILLE, N.C., Sept. 3, 2026 (GLOBE NEWSWIRE) -- Liquidia

Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging

respiratory and vascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation

to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP).

The potential use of YUTREPIA in SSc-RP is currently under clinical development, and its safety and efficacy for this indication have

not been evaluated by any regulatory authority.

Systemic sclerosis (SSc) is a rare, chronic autoimmune disease marked

by widespread vasculopathy and fibrosis of the skin and internal organs, and it carries the highest mortality of any systemic rheumatic

disease. Raynaud's phenomenon (RP) consists of recurrent, often severe vasospastic episodes that cause pain, numbness and color change

in the fingers and toes. Affecting up to 90% of SSc patients, these attacks are more frequent, prolonged and severe than primary Raynaud's,

often progressing to digital ischemic ulcers in an estimated 40% to 60% of patients and, in recurrent cases, digital amputation. At a

2020 FDA Patient-Focused Drug Development meeting, SSc patients identified Raynaud's attacks as among the disease's most bothersome and

impactful symptoms, citing pain, functional limitation and considerable emotional distress tied to fear of ulceration and tissue loss.

A central driver of SSc-RP is deficient endogenous prostacyclin production, which contributes to the vasospasm, platelet activation and

vascular remodeling underlying the disease. Liquidia estimates the addressable population of SSc-RP patients with moderate to severe symptoms

to be approximately 30,000 patients in the United States.

Dr. Rajeev Saggar, Chief Medical Officer, said: "Fast Track designation

reflects the seriousness of this condition and the need for new options. No therapy is currently approved by the FDA specifically for

SSc-RP. We are encouraged by the opportunity to evaluate whether YUTREPIA can reduce the complications of moderate to severe Raynaud’s

that most affect patients' quality of life, and we are committed to advancing this program with urgency, starting with the RE-WARM study

later this year."

The FDA's Fast Track program is designed to facilitate the development

and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. Fast Track designation provides

Liquidia with the opportunity for more frequent interactions with the FDA throughout development, the potential for rolling review of

a New Drug Application, and, if relevant criteria are met, potential eligibility for Priority Review and/or Accelerated Approval.

About RE-WARM

Liquidia plans to initiate RE-WARM (NCT07748000), a Phase 2a, randomized,

open-label, dose-finding study of YUTREPIA in approximately 75 adults with SSc experiencing symptomatic Raynaud's phenomenon attacks,

at up to approximately 30 sites in the United States. RE-WARM is designed to characterize the safety and pharmacodynamics of YUTREPIA

in this population. The study also explores whether treatment reduces the number, severity and impact of RP attacks. The study is expected

to begin in October 2026, with primary completion targeted for February 2027.

About YUTREPIA® (treprostinil) Inhalation Powder

YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered

through a convenient, low-effort, palm-sized device. YUTREPIA was designed using Liquidia's PRINT® technology, which enables the development

of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the

lung following oral inhalation. YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension

associated with interstitial lung disease (PH-ILD). YUTREPIA is not approved for the treatment of Raynaud's phenomenon associated with

systemic sclerosis, and there is no guarantee that the FDA will ultimately approve YUTREPIA for this use, even with Fast Track designation.

INDICATION

YUTREPIA (treprostinil) inhalation powder is a prostacyclin analog

indicated for the treatment of:

· Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.

Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic

or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

· Pulmonary hypertension associated with interstitial lung disease (PH-ILD;

WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic

interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE)

(25%), and WHO Group 3 connective tissue disease (22%).

SELECTED SAFETY INFORMATION: WARNINGS AND PRECAUTIONS

· Treprostinil is a pulmonary and systemic vasodilator. In patients with low

systemic arterial pressure, treatment with treprostinil may produce symptomatic hypotension.

· Treprostinil inhibits platelet aggregation and increases the risk of bleeding.

· Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g.,

gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin)

may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration,

whereas decreased exposure is likely to reduce clinical effectiveness.

· Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm.

Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm.

Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment.

· Most common adverse reactions with YUTREPIA (≥10%) are cough, headache,

throat irritation and dizziness.

Prescribing Information and Instructions for Use for YUTREPIA (treprostinil)

inhalation powder are available at https://www.yutrepia.com/full-prescribing-information.pdf.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company driven by science

and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company's current focus spans

the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology.

PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug approved for the treatment of pulmonary arterial

hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA is currently under development

for other indications, including SSc-RP. The company is also developing L606, an investigational extended-release formulation of treprostinil

administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH.

To learn more about Liquidia, please visit www.liquidia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release may include forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements

of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial

initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking

statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor,

anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related

submission contents and timelines, the receipt, timing and continuation of Fast Track designation and any benefits thereof, and our ability

to successfully develop and, if approved, commercialize YUTREPIA for SSc-RP or any other product candidate, involve significant risks

and uncertainties and actual results could differ materially from those expressed or implied herein. Fast Track designation does not guarantee

that YUTREPIA will receive FDA approval for the treatment of SSc-RP, that development will proceed on the anticipated timeline, or that

RE-WARM or any future study will produce favorable results. The words “anticipate,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,”

“predict,” “project,” “should,” “target,” “would,” and similar expressions

are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations

and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business

strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject

to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate

in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is

not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which

any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements

we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and

actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this

press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update

our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investors:

Jason Adair

Chief Business Officer

919.328.4350

Media:

media@liquidia.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Sep. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 03, 2026

Entity File Number

001-39724

Entity Registrant Name

LIQUIDIA

CORPORATION

Entity Central Index Key

0001819576

Entity Tax Identification Number

85-1710962

Entity Incorporation, State or Country Code

Entity Address, Address Line One

419

Davis Drive

Entity Address, Address Line Two

Suite

100

Entity Address, City or Town

Morrisville

Entity Address, State or Province

Entity Address, Postal Zip Code

27560

City Area Code

919

Local Phone Number

328-4400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock

Trading Symbol

LQDA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration